

Special Issue

Non-antiviral Agents for Treatment of COVID-19

Message from the Guest Editor

The novel coronavirus disease (COVID-19) continues to affect millions around the world, with no end in sight. A significant number of patients with COVID-19 who experienced exacerbated symptoms have died. Thus, saving the lives of patients with severe COVID-19 is currently of the highest importance. While antiviral agents, including those currently under development, are effective in the early phase of the disease, they are not effective for the late and advanced phases of COVID-19. Alternative approaches are required for these cases, including modulators for cytokines, inflammation inhibitors, and protective agents for tissue injury. The purpose of this Special Issue is to publish original research papers and/or relevant reviews of the most recent literature on the beneficial effects of non-antiviral agents for the treatment of moderate-to-severe COVID-19. Keywords: COVID-19; antiviral agents; cytokines; tissue-protective factors; moderate-to-severe pneumonia

Guest Editor

Dr. Toshihiro Kita
Frontier Science Research Center, University of Miyazaki, Miyazaki, Japan

Deadline for manuscript submissions

closed (31 August 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/93669

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).